User profiles for "author:Wan-Fai Ng"
Wan-Fai NgNewcastle University & Newcastle upon Tyne Hospitals NHS Foundation Trust Verified email at newcastle.ac.uk Cited by 17302 |
[PDF][PDF] Dendritic cells in transplantation—friend or foe?
R Lechler, WF Ng, RM Steinman - Immunity, 2001 - cell.com
DCs stimulated the growth and differentiation of CD4 New York, New York 10021 and CD8
alloreactive T cells, while, in the “efferent” phase, the activated T cells responded to other …
alloreactive T cells, while, in the “efferent” phase, the activated T cells responded to other …
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research
Fatigue is a complex phenomenon and an important health concern for many people with
chronic inflammatory rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis …
chronic inflammatory rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis …
Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations
P Brito-Zerón, E Theander, C Baldini… - Expert review of …, 2016 - Taylor & Francis
Sjögren's syndrome (SjS) is a systemic autoimmune disease that mainly affects the exocrine
glands, leading to generalized mucosal dryness. However, primary SjS may initially present …
glands, leading to generalized mucosal dryness. However, primary SjS may initially present …
Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells
Despite thymic deletion of cells with specificity for self-antigens, autoreactive T cells are
readily detectable in the normal T-cell repertoire. In recent years, a population of CD4+ T …
readily detectable in the normal T-cell repertoire. In recent years, a population of CD4+ T …
Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome
Sjögren's syndrome is a common autoimmune disease (affecting∼ 0.7% of European
Americans) that typically presents as keratoconjunctivitis sicca and xerostomia. Here we …
Americans) that typically presents as keratoconjunctivitis sicca and xerostomia. Here we …
EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies
M Ramos-Casals, P Brito-Zerón… - Annals of the …, 2020 - ard.bmj.com
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in
recent decades: treatment decisions remain challenging in clinical practice, without a …
recent decades: treatment decisions remain challenging in clinical practice, without a …
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity …
Objectives To define disease activity levels, minimal clinically important improvement (MCII)
and patient-acceptable symptom state (PASS) with the primary Sjögren's syndrome (SS) …
and patient-acceptable symptom state (PASS) with the primary Sjögren's syndrome (SS) …
Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal …
M Ramos-Casals, P Brito-Zerón, R Seror… - …, 2015 - academic.oup.com
Abstract Objective. To reach a European consensus on the definition and characterization of
the main organ-specific extraglandular manifestations in primary SS. Methods. The EULAR …
the main organ-specific extraglandular manifestations in primary SS. Methods. The EULAR …
Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)
R Seror, E Theander, JG Brun… - Annals of the …, 2015 - ard.bmj.com
Objectives To validate the two recently developed disease activity indexes for assessment of
primary Sjögren's syndrome (SS): the European League Against Rheumatism (EULAR) SS …
primary Sjögren's syndrome (SS): the European League Against Rheumatism (EULAR) SS …
Randomized controlled trial of rituximab and cost‐effectiveness analysis in treating fatigue and oral dryness in primary Sjögren's syndrome
SJ Bowman, CC Everett, JL O'Dwyer… - Arthritis & …, 2017 - Wiley Online Library
Objective To investigate whether rituximab, an anti–B cell therapy, improves symptoms of
fatigue and oral dryness in patients with primary Sjögren's syndrome (SS). Methods We …
fatigue and oral dryness in patients with primary Sjögren's syndrome (SS). Methods We …